BIBLIOGRAFÍA
2) Bartley GB, Gorman CA. Diagnostic Criteria for Graves Ophthalmopathy. Am J Ophtalmol 1995; 119(6): 792-5. 3) Jacobson D, Gorman C. Endocrine Ophthalmopathy: Current Ideas concerning etiology, pathogenesis and treatment. Endocrine Reviews 1984; 5: 200-20. 4) Weetman A. Thyroid associated eye disease: Pathophysiology Lancet 1991; 338(8758): 25-8. 5) Dobyns B, Steelman S. The Thyroid stimulating hormone of the anterior pituitary as distinct from the exophthalmos producing substance. Endocrinology 1953; 52: 705-7. 6) Ahmann A, Baker JR Jr. Weetman AP, Wartofsky L, Nutman TB, Burman KD. Antibodies to porcine eye muscle in patients with Graves' ophthalmopathy: identification of serum immunoglobulins directed against unique determinants by inummoblotting and enzyme-linked inummosorbent assay. J Clin Endocrinol Metab 1987; 64(3): 454-60. 7) Perros P, Crombie AL, Kendall Taylor P. Natural History of Thyroid associated Ophthalmopathy. Clin Endocrinol (Oxf) 1995; 42(1): 45-50. 8) Bech K. Thyroid Antibodies in Endocrine Ophthalmopathy. A review. Act Endocrinol 1989; 121 (Suppl 2): 117-22. 9) Becker J. Principles and Practice of Endocrinology and Metabolism. Philadelphia: Lippincott Company; 1995. Págs: 395-8. 10) Bartley G, Fatourechi V. The Incidence of Graves Ophthalmopathy in Olmsted County. Am J Ophthalm 1995; 120 (4): 511-7. 11) Wayne E. Diagnosis of Thyrotoxicosis. Br Med J 1954; 4859: 411-9. 12) Young J. Dysthyroid Ophthalmopathy in children. J Pediatr Oplitalm Strabismus 1979; 16(2):105-7. 13) McClintock J, Frawley T. Hyperthyroidism in Children: Observations in 50 treated cases, including an evaluation of Endocrine Factors. J Clin Endocrinol Metab 1956; (16): 62-85. 14) Uretsky S, Kennerdell JS, Gutai JP. Graves Ophthalmopathy in Childhood and Adolescence. Arch Ophthalmol 1980; 98(11): 1963-4. 15) McKendrick T, Newns GH. Thyrotoxicosis in Children: A follow up study. Arch Dis Child 1965; 40: 71-6. 16) Prummel M, Wiersinga WM. Smoking and Risk of graves Disease. JAMA 1993; 269(4) 479- 482. 17) Shine B, Fells P, Edwards OM, Weetman AP. Association between Graves Ophthalmopathy and Smoking. The Lancet 1990; 335(8700): 1261-3. 18) Cooper DS. Tobacco and Graves Disease: Smoking Gun or Smoke and Mirrors? (Editorial). JAMA 1993; 269 (4): 518-19. 19) Grubeck Loebenstein B, Trieb K, Sztankay A, Holter W, Anderl H, Wick G. Retrobulbar T Cells from patients with Graves' Ophthalmopathy are CD8+ and specifically recognize Autologous Fibroblasts. J Clin Invest 1994; 93(6): 2738-43. 20) Ericsson U, Lindgarde F. Effects of cigarette smoking on thyroid function and the prevalence of goiter, thyrotoxicosis and autoimmune thyroiditis. J Intern Med 1991; 229(1): 67-71. 21) Feliciello A, Porcellini A, Ciullo 1, BonavolontA.G, Avvedimento EV, Fenzi G. Expression of Thyrotropin-receptor mRNA in healthy and Graves' disease retroorbital tissue. Lancet 1993; 342(8867): 337-8. 22) Tallstead L, Lurdell G. Occurrence of Oplithalmopathy after treatment for Graves' Hyperthyroidism. N Eng J Med 1992; 326: 17338. 22) Wall J, 'Eriller H. Antibodies reactive with an intracellular Epitope of a recombinant 64 KDa Thyroid and Eye muscle protein in patients with thyroid autoinimunity and Ophthalmopathy. J. Endocrinol Invest 1993; 16: 863-8. 24) Atabay C, Tyutyunikov A. Serum Antibodies with eye muscle membrane antigens are detected in patients with non specific orbital inflammation. Ophthalmology 1995; 102 (1): 145-53. 25) Wall J, Hayes M. Native gel electrophoresis and isoelectric focusing of a 64 KDa eye muscle protein shows that it is an important target for serum antibodies in patients with thyroid associated Ophthalmopathy and not expressed in other skeletal muscle. J. Clin Endocrinol metab 1995; 80(4): 1226-32. 26) Zhang Z. Identification of antigenic Epitopes of ID antigen recognized by antibodies in serum of patients with thyroid associated ophthalmopathy. Clin Immunol Immunop 1995; 77: 193. 27) Barsouk A, Wengrowickz S. New Assays for the measurement of serum antibodies reactive with eye muscle membrane antigens confirm their significance in thyroid associated Ophthalmopathy. Thyroid 1995; 5(3): 195. 28) Tanaka k. Hiromatsu Y. Localization of Heat Protein Shock in Orbital Tissue from patients with Graves' Ophthalmopathy using in situ hybridization. Life Sciences 1993; 54: 355-9. 29) Hiromatsu Y. Tanaka K. Human histocompatibility leukocyte Antigen DR and Heat Shock Protein 70 Expression in eye muscle tissue in thyroid Ophthalmopathy. J Clin. Endoc Metabolism 1995; 80(2): 68591. 30) Salvi M, Bernard N. Prevalence of Antibodies Reactive with a 64 KDa Eye Muscle Membrane Antigen in Thyroid Associated Ophthalmopathy. Thyroid 1993; 1(3): 207-13. 31) Sergott R, Glasser J. Graves Ophthalmopathy. A clinical and immunologic Review. Surv Ophthalmol 198 1; 26 (1): 1-21. 32) Horace K, Iv Y. Medical Approach to Ophthalmopathy of Graves' Disease. Mayo Clinic Proc 1972; 47: 980-5. 33) Marcocci C, Bartalena L. Recent Progress in Graves Ophthalmopathy. Current Opinion in Endocrinology & Diabetes 1996; 3(5): 417-21. 34) De Bellis A, Bizzarro A. Behavior of Soluble Intercellular Adhesion Molecule-1 and Endotelial-Leucocyte Adhesion Molecule - I concentrations in patients with toxic adenoma. J Clin Endocrinol Metabolism 1995; 80 (7): 2118-21. 35) Smith T, Bahn A. Stimulation of Glycosaminoglycan accumulation by Interferon in cultured human retroocular fibroblasts. J. Clin, Endocrinol. Metabolism 199 1; 72: 1169-71. 36) Hasfelder A, Dutton C. Detectation of TSH-Receptor RNA in cultured fibroblasts from patients with Graves' Ophthalmopathy and Pretibial Dermopathy. Thyroid 1993; 3: 297-300. 37) Trieb K, Sztankay A. Do Heat Shock Proteins play a role in Graves' Disease? J Clin Endocrinol Metabolism 1993; 77 (2): 528-34. 38) Mc Lachlan S, Prummel M. Immunoglobulin A in Graves' orbital tissue: Deoxyribonucleic acid amplification by polymerase chain reaction J Endocrinol Invest. 1994; 17: 247-52. 39) Molnar I, Balazs C. IgA Anti-eye muscle cytosol autoantibodies and the clinical stage in Graves' disease. J. Endocrinol Invest. 1994; 17: 671. 40) Char D. Thyroid Eye Disease. 1997. Third Edition. Pags. 37-57 41) Werner S. Modification of the Classification of the Eye Changes of Graves' Disease. Recommendations of the Ad Hoc Committee of the ATA. J Clin Endocrinol Metabolism 1977; 44: 203. 42) Polil A. Parámetros Clínicos para establecer los índices de Frecuencia y grados de severidad en el Hipertiroidismo, forma Graves Basedow. II Congreso Peruano de Endocrinología. 1985, Noviembre 21. 43) Ferrán Ananaz M. SPSS para Windows. Programación y Análisis Estadístico. Serie McGraw-Hill de Informática. Madrid: McGraw-Hill; 1995. 44) Cartalena L, Marcocci C. Cytokine Antagonists: New Ideas for the Management of Graves' Ophthalmopathy. J Clin Endoc Metabolism 1996; 31: 446-8. 45) Burch H, Selliti D. Thyrotropin Receptor Antisera for the Detection of Immunoreactive Protein Species in Retroocular Fibroblasts Obtained from Patients with Graves' Ophthalmopathy. J Clin Endocrinol Metabolism 1994; 78(6): 1384-91. 46) Perros P, Crombie A. Age and Gender influence the severity of thyroid associated Ophthalmopathy: a study of 101 patients attended a combined thyroid eye clinic. Clinic Endocrinol 1993; 38, 367-72. 47) Niño J. Hallazgos Clínicos en la Oftalmopatía de Graves en el Hospital Nacional Dos de Mayo. Octubre 1991 a Mayo 1996. 1996. Tesis de Especialidad. UNNISM. 48) Carrasco De la Peña J, Herran M. Estadística Multivariada en las Ciencias de la Vida. Editorial Ciencia 3. 1993. 49) Lawton N, Fells P. Medical Investigation of Dysthyroid Eye Disease. Third International Symposium on orbital Disorders Headed by Orbital Center Amsterdam. 1978; 343. |
